{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T14:57:04Z","timestamp":1777906624512,"version":"3.51.4"},"reference-count":23,"publisher":"S. Karger AG","issue":"5","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Res Treat"],"published-print":{"date-parts":[[2019]]},"abstract":"<b><i>Background:<\/i><\/b> Pegylated liposomal doxorubicin (PEG-LD) has a comparable efficacy but a distinct toxicological profile compared with free doxorubicin. The use of PEG-LD and cyclophosphamide followed by docetaxel regimen as neoadjuvant chemotherapy has not been well established. <b><i>Objectives:<\/i><\/b> We aimed to assess the maximum tolerated dose (MTD) and toxicity of this regimen in patients with locally advanced breast cancer. <b><i>Methods:<\/i><\/b> A total of 19 patients were enrolled in this trial. In the initial treatment plan, patients were given PEG-LD at 35, 40, 45, or 50 mg\/m<sup>2<\/sup> on day 1 during the first four cycles, and cyclophosphamide was administered at a dose of 600 mg\/m<sup>2<\/sup>. During the last four cycles, docetaxel was administered at 75 mg\/m<sup>2<\/sup> on day 1 of a 21-day scheme. <b><i>Results:<\/i><\/b> The MTD was 40 mg\/m<sup>2<\/sup> PEG-LD and 600 mg\/m<sup>2<\/sup> cyclophosphamide administered on day 1 of a 21-day cycle. Dose-limiting toxicity, grade 3 hand-foot syndrome, was observed in one patient during level 2 and three patients during level 3. Other side effects included neutropenia, anemia, stomatitis, rash, nausea\/vomiting, alopecia, transaminase elevation, and cardiotoxicity. The pathological complete response rate was 21.1%. <b><i>Conclusions:<\/i><\/b> Our study demonstrated that combination of 40 mg\/m<sup>2<\/sup> PEG-LD and 600 mg\/m<sup>2<\/sup> cyclophosphamide, followed by 75 mg\/m<sup>2<\/sup> docetaxel on day 1 of a 21-day scheme, was an efficacious and well-tolerated neoadjuvant regimen for patients with locally advanced breast cancer.<\/jats:p>","DOI":"10.1159\/000498993","type":"journal-article","created":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T21:55:32Z","timestamp":1554328532000},"page":"269-274","source":"Crossref","is-referenced-by-count":6,"title":["A Dose-Escalating Pilot Study (NCT03017404) of Pegylated Liposomal Doxorubicin and Cyclophosphamide, Followed by Docetaxel Administration as a Neoadjuvant Chemotherapy Regimen in Patients with Locally Advanced Breast Cancer"],"prefix":"10.1159","volume":"42","author":[{"given":"Meng","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenchuan","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixin","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinle","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajie","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2019,4,3]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn085"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342050-00002"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2003.n.037"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.7.1777"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.0235"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.232"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199809243391307"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.1.37"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008216430806"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008365716693"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh097"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2165\/11207510-000000000-00000"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.5.1906"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199937030-00002"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0033"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-015-3415-2"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2005.n.017"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.7504"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf284"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2004.01.006"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3892\/or.10.6.1817"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.12.005"}],"container-title":["Oncology Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/498993","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/498993","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:23:54Z","timestamp":1745425434000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000498993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,5,2]]},"published-print":{"date-parts":[[2019,5,8]]}},"URL":"https:\/\/doi.org\/10.1159\/000498993","archive":["Portico"],"relation":{},"ISSN":["2296-5270","2296-5262"],"issn-type":[{"value":"2296-5270","type":"print"},{"value":"2296-5262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}